Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation
Open Access
- 8 July 2024
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82170206)
- Shanghai Municipal Health Commission Project of Disciplines of Excellence
This publication has 14 references indexed in Scilit:
- Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantationLeukemia, 2024
- Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemiaAmerican Journal of Hematology, 2024
- PASS‐ALL study of paediatric‐inspired versus adult chemotherapy regimens on survival of high‐risk Philadelphia‐negative B‐cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantationBritish Journal of Haematology, 2023
- A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission MaintenanceBlood, 2023
- Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL studyBritish Journal of Haematology, 2023
- Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemiaBone Marrow Transplantation, 2023
- A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort studyLeukemia, 2020
- Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2019
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaBlood, 2018
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2017